Movatterモバイル変換

[0]ホーム
URL:

WO2002102994A3 - Human secreted proteins - Google Patents

Human secreted proteinsDownload PDF

Info

Publication number
WO2002102994A3
WO2002102994A3PCT/US2002/008278US0208278WWO02102994A3WO 2002102994 A3WO2002102994 A3WO 2002102994A3US 0208278 WUS0208278 WUS 0208278WWO 02102994 A3WO02102994 A3WO 02102994A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
human secreted
polynucleotides
encompassed
Prior art date
Application number
PCT/US2002/008278
Other languages
French (fr)
Other versions
WO2002102994A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven M RubenfiledCriticalHuman Genome Sciences Inc
Priority to EP02760994ApriorityCriticalpatent/EP1379132A4/en
Priority to CA002441832Aprioritypatent/CA2441832A1/en
Priority to AU2002326293Aprioritypatent/AU2002326293A1/en
Publication of WO2002102994A2publicationCriticalpatent/WO2002102994A2/en
Publication of WO2002102994A3publicationCriticalpatent/WO2002102994A3/en
Priority to US11/346,470prioritypatent/US20060223088A1/en
Priority to US12/198,817prioritypatent/US7968689B2/en

Links

Classifications

Landscapes

Abstract

The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating immune disorders and diseases. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
PCT/US2002/0082781997-03-072002-03-19Human secreted proteinsWO2002102994A2 (en)

Priority Applications (5)

Application NumberPriority DateFiling DateTitle
EP02760994AEP1379132A4 (en)2001-03-212002-03-19Human secreted proteins
CA002441832ACA2441832A1 (en)2001-03-212002-03-19Human secreted proteins
AU2002326293AAU2002326293A1 (en)2001-03-212002-03-19Human secreted proteins
US11/346,470US20060223088A1 (en)1997-03-072006-02-03Human secreted proteins
US12/198,817US7968689B2 (en)1997-03-072008-08-26Antibodies to HSDEK49 polypeptides

Applications Claiming Priority (6)

Application NumberPriority DateFiling DateTitle
US27734001P2001-03-212001-03-21
US60/277,3402001-03-21
US30617101P2001-07-192001-07-19
US60/306,1712001-07-19
US33128701P2001-11-132001-11-13
US60/331,2872001-11-13

Related Parent Applications (2)

Application NumberTitlePriority DateFiling Date
US09/981,876Continuation-In-PartUS7053190B2 (en)1997-03-072001-10-19Secreted protein HRGDF73
US10/100,683Continuation-In-PartUS7368531B2 (en)1997-03-072002-03-19Human secreted proteins

Related Child Applications (2)

Application NumberTitlePriority DateFiling Date
US10472532A-371-Of-International2002-03-19
US11/346,470Continuation-In-PartUS20060223088A1 (en)1997-03-072006-02-03Human secreted proteins

Publications (2)

Publication NumberPublication Date
WO2002102994A2 WO2002102994A2 (en)2002-12-27
WO2002102994A3true WO2002102994A3 (en)2003-07-24

Family

ID=27402891

Family Applications (7)

Application NumberTitlePriority DateFiling Date
PCT/US2002/009785WO2002095010A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008279WO2002090526A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008124WO2003004622A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008276WO2002076488A1 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008278WO2002102994A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008123WO2002102993A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008277WO2003038063A2 (en)2001-03-212002-03-19Human secreted proteins

Family Applications Before (4)

Application NumberTitlePriority DateFiling Date
PCT/US2002/009785WO2002095010A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008279WO2002090526A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008124WO2003004622A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008276WO2002076488A1 (en)1997-03-072002-03-19Human secreted proteins

Family Applications After (2)

Application NumberTitlePriority DateFiling Date
PCT/US2002/008123WO2002102993A2 (en)1997-03-072002-03-19Human secreted proteins
PCT/US2002/008277WO2003038063A2 (en)2001-03-212002-03-19Human secreted proteins

Country Status (4)

CountryLink
EP (7)EP1379264A4 (en)
AU (6)AU2002326293A1 (en)
CA (7)CA2441397A1 (en)
WO (7)WO2002095010A2 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7319006B2 (en)1998-06-012008-01-15Genentech, Inc.Serpentine transmembrane antigens expressed in human cancers and uses thereof
US8859741B2 (en)2007-08-232014-10-14Amgen Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883157B1 (en)2013-12-172014-11-11Kymab LimitedTargeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en)2014-07-152015-02-03Kymab LimitedMethod of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en)2014-07-152015-03-17Kymab LimitedMethod of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en)2014-07-152015-03-24Kymab LimitedMethod of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en)2014-07-152015-03-24Kymab LimitedTargeting human nav1.7 variants for treatment of pain
US8992927B1 (en)2014-07-152015-03-31Kymab LimitedTargeting human NAV1.7 variants for treatment of pain
US8999341B1 (en)2014-07-152015-04-07Kymab LimitedTargeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en)2014-07-152015-04-28Kymab LimitedMethod of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en)2014-07-152015-05-19Kymab LimitedPrecision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en)2014-07-152015-06-23Kymab LimitedPrecision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9109034B1 (en)2014-07-152015-08-18Kymab LimitedPrecision medicine by targeting PD-L1 variants for treatment of cancer
US9139648B1 (en)2014-07-152015-09-22Kymab LimitedPrecision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en)2014-07-152015-10-06Kymab LimitedPrecision Medicine by targeting human NAV1.8 variants for treatment of pain
US9593167B2 (en)2006-10-272017-03-14Genentech, Inc.Antibodies and immunoconjugates and uses therefor
US9617346B2 (en)2004-04-222017-04-11Agensys, Inc.Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en)2017-04-032021-11-23Hoffmann-La Roche Inc.Antibodies binding to STEAP-1

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO1999002546A1 (en)1997-07-081999-01-21Human Genome Sciences, Inc.123 human secreted proteins
US7196164B2 (en)1997-07-082007-03-27Human Genome Sciences, Inc.Secreted protein HHTLF25
US20030149531A1 (en)2000-12-062003-08-07Hubert Rene S.Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE69941187D1 (en)1998-06-012009-09-10Agensys Inc SERPENTINTRANSMEMBRANANTIGENE EXPRESSED IN HUMAN CANCER AND ITS USES
US20060052321A1 (en)2002-04-052006-03-09Raitano Arthur BNucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en)1998-06-012004-07-22Raitano Arthur B.Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
BR0007556A (en)1999-01-152001-10-23Biogen Inc Tweak and tweak receptor antagonists and their use to treat immune disorders
EP1666490A3 (en)*2000-07-252006-11-02Genentech, Inc.Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7335731B2 (en)2000-07-252008-02-26Genentech, Inc.PRO4332 polypeptides
EP1364021A2 (en)2000-10-312003-11-26Diadexus, Inc.Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en)*2000-11-302002-08-15Y. Tom TangNovel nucleic acids and polypeptides
EP2280030A3 (en)2001-04-102011-06-15Agensys, Inc.Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en)2001-06-202003-06-26Genentech, Inc.Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en)2001-09-062009-02-24Agensys, Inc.Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2532757T3 (en)2001-09-062015-03-31Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
CA2463596A1 (en)2001-10-122003-04-24Yamanouchi Pharmaceutical Co., Ltd.Method of screening cell death inhibitor
KR101000842B1 (en)2002-04-092010-12-14바이오겐 아이덱 엠에이 인코포레이티드 How to treat TVE-related conditions
AU2003900747A0 (en)*2003-02-182003-03-06Garvan Institute Of Medical ResearchDiagnosis and treatment of pancreatic cancer
US7709610B2 (en)2003-05-082010-05-04Facet Biotech CorporationTherapeutic use of anti-CS1 antibodies
US20050025763A1 (en)2003-05-082005-02-03Protein Design Laboratories, Inc.Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en)*2003-08-112005-03-03Genentech, Inc.Compositions and methods for the treatment of immune related diseases
ATE455174T1 (en)2003-09-232010-01-15Univ North Carolina CELLS THAT COEXPRESS VITAMIN K REDUCTASE AND VITAMIN K DEPENDENT PROTEIN AND THEIR APPLICATION TO IMPROVE THE PRODUCTIVITY OF THIS VITAMIN K DEPENDENT PROTEIN
ES2515216T3 (en)*2003-10-142014-10-29Baxter International Inc VKORC1 polypeptide for recycling vitamin K-epoxide, a therapeutic target of coumarin and its derivatives
EP1714154A2 (en)*2004-02-032006-10-25Bayer HealthCare AGDiagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en)2004-02-202005-08-25Yixin WangBreast cancer prognostics
DK1794174T3 (en)*2004-09-012012-07-09Dynavax Tech Corp PROCEDURES AND COMPOSITIONS FOR INHIBITING CURRENT IMMUNE RESPONSES AND AUTO-IMMUNITY
WO2006026807A1 (en)*2004-09-072006-03-16Telethon Institute For Child Health ResearchAgents for treatment or prevention of an allergic disorder
JP2008512100A (en)*2004-09-072008-04-24テレソン インスティテュート フォー チャイルド ヘルス リサーチ Method for diagnosis and / or prediction of onset of allergic diseases
CA2597945C (en)2005-02-172016-07-12Biogen Idec Ma Inc.Treating neurological disorders
PT1853700E (en)2005-02-282013-01-14Baxter IntRecombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression
JP2008532544A (en)2005-03-152008-08-21ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for producing active vitamin K-dependent proteins
JP5339901B2 (en)2005-05-102013-11-13バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment and evaluation of inflammatory injury
WO2006138219A2 (en)2005-06-132006-12-28Biogen Idec Ma Inc.Methods of diagnosis / prognosis of inflammatory conditions
GB2445882B (en)*2005-09-012011-02-23Florey Howard InstProphylactic and therapeutic agents and compositions and uses therefor and methods for determining the presence or severity of neuronal damage
GB0521488D0 (en)*2005-10-212005-11-30Ares Trading SaIntegral membrane protein
US7572618B2 (en)2006-06-302009-08-11Bristol-Myers Squibb CompanyPolynucleotides encoding novel PCSK9 variants
US20100041102A1 (en)2006-11-072010-02-18Ayesha SitlaniAntagonists of pcsk9
US8093222B2 (en)2006-11-272012-01-10Isis Pharmaceuticals, Inc.Methods for treating hypercholesterolemia
US8263353B2 (en)2007-03-272012-09-11Merck Sharp & Dohme Corp.Method for detecting autoprocessed, secreted PCSK9
JP5749492B2 (en)2007-10-262015-07-15ダイナバックス テクノロジーズ コーポレイション Methods and compositions for inhibiting immune responses and autoimmunity
WO2009070350A1 (en)*2007-11-302009-06-04Siemens Healthcare Diagnostics Inc.Adiponectin receptor fragments and methods of use
AR070316A1 (en)2008-02-072010-03-31Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en)2008-02-072010-03-31Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2010068526A1 (en)2008-12-122010-06-17Merck Sharp & Dohme Corp.Pcsk9 immunoassay
AU2010313381A1 (en)2009-10-302012-04-12Merck Sharp & Dohme Corp.AX1 and AX189 PCSK9 antagonists and variants
EP2493507A4 (en)2009-10-302013-11-20Merck Sharp & Dohme ANTAGONISTS AND VARIANTS AX213 AND AX132 PCSK9
CN103153346A (en)2010-06-162013-06-12戴纳瓦克斯技术公司Methods of treatment using tlr7 and/or tlr9 inhibitors
CA2810928A1 (en)2010-09-222012-03-29Alios Biopharma, Inc.Substituted nucleotide analogs
EP2655607A4 (en)2010-12-212014-05-14Univ North Carolina METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ACTIVE PROTEINS DEPENDENT ON VITAMIN K
WO2013096680A1 (en)2011-12-222013-06-27Alios Biopharma, Inc.Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en)2012-03-212013-09-26Vertex Pharmaceuticals IncorporatedSolid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en)2012-03-222015-10-28Alios Biopharma IncPharmaceutical combinations comprising a thionucleotide analog
US9067998B1 (en)2014-07-152015-06-30Kymab LimitedTargeting PD-1 variants for treatment of cancer
US9045548B1 (en)2014-07-152015-06-02Kymab LimitedPrecision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en)2014-07-152015-06-09Kymab LimitedTargeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en)2013-12-232017-06-20Carefusion 2200, Inc.Pleurodesis device and method
GB201403775D0 (en)2014-03-042014-04-16Kymab LtdAntibodies, uses & methods
WO2017220989A1 (en)2016-06-202017-12-28Kymab LimitedAnti-pd-l1 and il-2 cytokines
EP3534947A1 (en)2016-11-032019-09-11Kymab LimitedAntibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3048479A1 (en)2016-12-232018-06-28President And Fellows Of Harvard CollegeGene editing of pcsk9
WO2018237212A1 (en)2017-06-222018-12-27The Procter & Gamble Company FILMS COMPRISING A WATER-SOLUBLE LAYER AND AN ORGANIC COATING DEPOSITED IN STEAM PHASE
US10450119B2 (en)2017-06-222019-10-22The Procter & Gamble CompanyFilms including a water-soluble layer and a vapor-deposited inorganic coating
IL297193A (en)2020-04-092022-12-01Verve Therapeutics IncBase editing of pcsk9 and methods of using same for treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
KR100236393B1 (en)*1996-02-021999-12-15나까니시 히로유끼A pharmaceutical preparation containing a human growth hormone
WO2002026931A2 (en)*2000-09-252002-04-04Human Genome Sciences, Inc.71 human secreted proteins
US5858716A (en)*1997-05-301999-01-12Smithkline Beecham CorporationH2CAA71 polynucleotides
CA2333917A1 (en)*1998-07-152000-01-27Human Genome Sciences, Inc.71 human secreted proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] SANGER CENTRE, HINXTON, UK; 27 November 2000 (2000-11-27), PEARCE A.: "Human DNA sequence from clone RP11-50D16 on chromosome 13, complete sequence", XP002963946, accession no. EMBL Database accession no. (AL445590)*
See also references ofEP1379132A4*

Cited By (35)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7319006B2 (en)1998-06-012008-01-15Genentech, Inc.Serpentine transmembrane antigens expressed in human cancers and uses thereof
US9617346B2 (en)2004-04-222017-04-11Agensys, Inc.Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en)2004-04-222020-03-24Agensys, Inc.Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11401347B2 (en)2004-04-222022-08-02Agensys, Inc.Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9593167B2 (en)2006-10-272017-03-14Genentech, Inc.Antibodies and immunoconjugates and uses therefor
US8889834B2 (en)2007-08-232014-11-18Amgen Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883983B2 (en)2007-08-232014-11-11Amgen Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871913B2 (en)2007-08-232014-10-28Amgen Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8981064B2 (en)2007-08-232015-03-17Amgen Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871914B2 (en)2007-08-232014-10-28Amgen, Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8859741B2 (en)2007-08-232014-10-14Amgen Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9493576B2 (en)2007-08-232016-11-15Amgen Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883157B1 (en)2013-12-172014-11-11Kymab LimitedTargeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en)2014-07-152015-05-19Kymab LimitedPrecision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9394568B2 (en)2014-07-152016-07-19Kymab LimitedMethods of treating anaemia
US9023359B1 (en)2014-07-152015-05-05Kymab LimitedTargeting rare human PCSK9 variants for cholesterol treatment
US8999341B1 (en)2014-07-152015-04-07Kymab LimitedTargeting rare human PCSK9 variants for cholesterol treatment
US9034331B1 (en)2014-07-152015-05-19Kymab LimitedTargeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en)2014-07-152015-06-23Kymab LimitedPrecision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9109034B1 (en)2014-07-152015-08-18Kymab LimitedPrecision medicine by targeting PD-L1 variants for treatment of cancer
US9139648B1 (en)2014-07-152015-09-22Kymab LimitedPrecision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en)2014-07-152015-10-06Kymab LimitedPrecision Medicine by targeting human NAV1.8 variants for treatment of pain
US9187562B1 (en)2014-07-152015-11-17Kymab LimitedMethods for treating anaemia
US9303089B2 (en)2014-07-152016-04-05Kymab LimitedMethods of treating anaemia
US9017678B1 (en)2014-07-152015-04-28Kymab LimitedMethod of treating rheumatoid arthritis using antibody to IL6R
US9428578B2 (en)2014-07-152016-08-30Kymab LimitedMethods of treating anaemia
US9439963B2 (en)2014-07-152016-09-13Kymab LimitedMethods of treating anaemia
US8992927B1 (en)2014-07-152015-03-31Kymab LimitedTargeting human NAV1.7 variants for treatment of pain
US8986694B1 (en)2014-07-152015-03-24Kymab LimitedTargeting human nav1.7 variants for treatment of pain
US8986691B1 (en)2014-07-152015-03-24Kymab LimitedMethod of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en)2014-07-152015-03-17Kymab LimitedMethod of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en)2014-07-152015-02-03Kymab LimitedMethod of treating rheumatoid arthritis using antibody to IL6R
US11180571B2 (en)2017-04-032021-11-23Hoffmann-La Roche Inc.Antibodies binding to STEAP-1
US11685790B2 (en)2017-04-032023-06-27Hoffmann-La Roche Inc.Antibodies binding to STEAP-1
US12129306B2 (en)2017-04-032024-10-29Hoffman-La Roche Inc.Antibodies binding to STEAP-1

Also Published As

Publication numberPublication date
AU2002332391A1 (en)2003-01-02
WO2002090526A2 (en)2002-11-14
CA2441397A1 (en)2002-10-03
WO2002090526A3 (en)2003-10-30
EP1390390A2 (en)2004-02-25
AU2002324424A1 (en)2002-12-03
CA2441832A1 (en)2002-12-27
EP1379132A4 (en)2009-07-01
WO2003004622A2 (en)2003-01-16
EP1379132A2 (en)2004-01-14
EP1423134A2 (en)2004-06-02
WO2002095010A3 (en)2004-02-12
CA2441840A1 (en)2002-11-28
AU2002354719A1 (en)2003-01-21
WO2002076488A1 (en)2002-10-03
EP1379264A4 (en)2009-07-08
EP1381622A2 (en)2004-01-21
EP1379264A1 (en)2004-01-14
CA2441416A1 (en)2003-01-16
EP1390390A4 (en)2009-07-08
WO2003004622A3 (en)2004-02-19
WO2002102994A2 (en)2002-12-27
CA2441702A1 (en)2002-12-27
WO2002102993A3 (en)2004-03-25
WO2002102993A2 (en)2002-12-27
CA2441755A1 (en)2003-05-08
WO2002095010A2 (en)2002-11-28
AU2002320013A1 (en)2002-11-18
AU2002326293A1 (en)2003-01-02
CA2441417A1 (en)2002-11-14
EP1404702A2 (en)2004-04-07
WO2003038063A3 (en)2003-12-11
EP1414845A2 (en)2004-05-06
AU2002363296A1 (en)2003-05-12
EP1414845A4 (en)2009-07-08
EP1404702A4 (en)2009-07-08
WO2003038063A2 (en)2003-05-08

Similar Documents

PublicationPublication DateTitle
WO2002102994A3 (en)Human secreted proteins
WO2002077186A3 (en)Human secreted proteins
WO2001055310A8 (en)Nucleic acids, proteins, and antibodies
WO2001054472A3 (en)Nucleic acids, proteins, and antibodies
WO2001055306A3 (en)Nucleic acids, proteins, and antibodies
WO2001055326A3 (en)Nucleic acids, proteins, and antibodies
WO2004042000A3 (en)157 human secreted proteins
WO2001055168A8 (en)Nucleic acids, proteins and antibodies
WO2002072763A3 (en)Nucleic acids, proteins, and antibodies
WO2001055167A8 (en)Nucleic acids, proteins, and antibodies
WO2001055162A8 (en)Nucleic acids, proteins, and antibodies
WO2001055305A3 (en)Nucleic acids, proteins, and antibodies

Legal Events

DateCodeTitleDescription
AKDesignated states

Kind code of ref document:A2

Designated state(s):AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

ALDesignated countries for regional patents

Kind code of ref document:A2

Designated state(s):GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121Ep: the epo has been informed by wipo that ep was designated in this application
WWEWipo information: entry into national phase

Ref document number:2441832

Country of ref document:CA

WWEWipo information: entry into national phase

Ref document number:2002760994

Country of ref document:EP

DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWPWipo information: published in national office

Ref document number:2002760994

Country of ref document:EP

REGReference to national code

Ref country code:DE

Ref legal event code:8642

NENPNon-entry into the national phase

Ref country code:JP

WWWWipo information: withdrawn in national office

Country of ref document:JP
[8]ページ先頭
©2009-2025 Movatter.jp